FAQ on Calidi Biotherapeutics Inc. (NYSE American: CLDI) Q2 2025 Results and Business Highlights
Summary
Calidi Biotherapeutics reported a reduced net loss in Q2 2025 compared to Q2 2024, alongside significant business advancements including FDA Fast Track Designation for CLD-201 and new preclinical data on CLD-401.
What were Calidi Biotherapeutics’ financial results for Q2 2025?
Calidi Biotherapeutics reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, an improvement from a net loss of $7.4 million, or $16.75 per share, in Q2 2024.
How did Calidi Biotherapeutics’ R&D and G&A expenses change in Q2 2025 compared to the previous year?
R&D expenses increased to $2.6 million from $2.2 million, while G&A expenses decreased to $3.1 million from $3.6 million compared to the previous year.
What recent business highlights did Calidi Biotherapeutics announce?
Recent highlights include new preclinical data on CLD-401, $4.6 million raised in a warrant inducement offering, and FDA Fast Track Designation for CLD-201 in soft tissue sarcoma.
What is the significance of the FDA Fast Track Designation for CLD-201?
The FDA Fast Track Designation for CLD-201 accelerates the development and review process for treating soft tissue sarcoma, indicating its potential to address unmet medical needs.
What is Calidi Biotherapeutics’ RedTail platform?
The RedTail platform is Calidi’s proprietary technology featuring an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to shield the virus from immune clearance.
What are the target diseases for Calidi Biotherapeutics’ lead candidate from the RedTail platform?
The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.
How much cash did Calidi Biotherapeutics have at the end of Q2 2025?
Calidi ended the quarter with $5.3 million in cash and $0.1 million in restricted cash.
Where can I find more information about Calidi Biotherapeutics?
The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI.
What is TinyGems?
TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio at IBN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 145562